Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Author Archives: Warren Woessner
SACGHS Final Report on Gene Patents – Taking a Machete to the IP Thicket
On September 17, 2009, the Secretary of HHS’s Advisory Committee on Genetics, Health and Society (SACGHS) issued a Final Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests. The 66 page report … Continue reading
Posted in Patent Eligible Subject Matter
Tagged gene patents, patents, SACGHS, Warren Woessner
Leave a comment
Court Decision in China Recognizes Novelty in Dosage Limitations in Swiss-Form Claims
Peksung Intellectual Property Ltd sent an interesting article (link below) reporting that the Higher People’s Court of Beijing held that both dosage form and dosage amount should be treated as limitations in Swiss-form claims. These “administration-related features” are often ignored … Continue reading
Posted in Non-U.S. Practice
Tagged china patent law, Patent Law, SIPO, Warren Woessner
Leave a comment
ESTHER KEPPLINGER JOINS PATENT PUBLIC ADVISORY COMMITTEE
I would like to congratulate Esther Kepplinger on her appointment by Commerce Secretary Locke to the Patent Public Advisory Committee, along with Steven W. Miller of P&G and Dr. Benjamin Borson. Although I have not always been sure just what … Continue reading
WILL THE NIGHTMARE FOR BIOTECH PREP/PROS NEVER END?
I recently gave a talk on patenting biomarkers, and was asked to talk about “push-back” by the courts and the PTO against getting useful patent claims in this emerging area (the gateway to “personalized medicine.” I was struck with how … Continue reading
Posted in USPTO Practice and Policy
Tagged Bilski, DNA, in re kubin, Warren Woessner, WDR
Leave a comment